Raghavendra Nulgumnalli Manjunathaiah

About

My research program is focused on the integrated approaches for drug discovery including computer-aided drug design, medicinal chemistry, and cell biology experiments to investigate and address the therapeutic strategies in treating cancer diseases. At present, I am working towards targeting HSP90 and BRAF proteins. Molecular mechanics and molecular dynamics approaches are explored to understand the structure, reactivity, and function of small molecules with target proteins. Develop novel cost-effective synthetic routes for the lead compounds. Besides, I also work on providing a hypothesis to the mechanism of drug action with in vitro cell-based experiments and proteomic analysis.

Employment

• Dayananda Sagar University Professor & Principal
  2022 - Present
• Acharya Institutes R&D Head
  2018 - 2022
• Fundação Oswaldo Cruz Postdoctoral Fellow
  2015 - 2018
• Purdue University Postdoctoral Fellow
  2012 - 2013
• Gokaraju Rangaraju College of Pharmacy Professor & Head
  2008 - 2015
• Acharya Institutes Lecturer
  2003 - 2008

Education

• Birla Institute of Technology and Science PhD.
  2004 - 2008
• Rajiv Gandhi University of Health Sciences M. Pharm
  2001 - 2003

Projects & Funding

Projects & funding information is unavailable.

Publications (45)

• EGFR as therapeutic target to develop new generation tyrosine kinase inhibitors against breast cancer: A critical review
  Results in Chemistry 2024 DOI: 10.1016/j.rechem.2024.101490
  +Save
• Medicinal Chemistry Perspectives on Recent Advances in Src Kinase Inhibitors as a Potential Target for the Development of Anticancer Agents: Biological Profile, Selectivity, Structure-Activity Relationship.
  Chemistry & biodiversity 2023 DOI: 10.1002/cbdv.202300515
  +Save
• Molecular recognition of some novel mTOR kinase inhibitors to develop anticancer leads by drug-likeness, molecular docking and molecular dynamics based virtual screening strategy
  Computational Toxicology 2023 DOI: 10.1016/j.comtox.2022.100257
  +Save
• Design, Synthesis, In‐silico Studies and Antiproliferative Evaluation of Novel Indazole Derivatives as Small Molecule Inhibitors of B‐Raf
  ChemistrySelect 2023 DOI: 10.1002/slct.202300291
  +Save
• An updated literature on BRAF inhibitors (2018-2023).
  Molecular diversity 2023 DOI: 10.1007/s11030-023-10699-3
  +Save
• Mechanistic insights into the beneficial effects of curcumin on insulin resistance: Opportunities and challenges.
  Drug discovery today 2023 DOI: 10.1016/j.drudis.2023.103627
  +Save
• Pharmacophore modeling, virtual screening, molecular docking and dynamics studies for the discovery of HER2-tyrosine kinase inhibitors: An in-silico approach
  Journal of Molecular Structure 2022 DOI: 10.1016/j.molstruc.2022.132531
  +Save
• Current updates on EGFR and HER2 tyrosine kinase inhibitors for the breast cancer
  Medicinal Chemistry Research 2022 DOI: 10.1007/s00044-022-02934-7
  +Save
• Computational analysis of natural product B-Raf inhibitors
  Journal of Molecular Graphics and Modelling 2022 DOI: 10.1016/j.jmgm.2022.108340
  +Save
• Discoidin Domain Receptor Inhibitors as Anticancer Agents: A Systematic Review on Recent Development of DDRs Inhibitors, their Resistance and Structure Activity Relationship
  Bioorganic Chemistry 2022 DOI: 10.1016/j.bioorg.2022.106215
  +Save